质子抑制剂和痴呆症:有什么关联?
Catarina Caetano1, Marta Veloso1, Susana Borda1
1Unidade de Saúde Familiar Delta, Administração Regional de Saúde de Lisboa e Vale do Tejo, Oeiras, Lisboa, Portugal.
Dementia & neuropsychologia
|June 1, 2023
概括
质子抑制剂 (PPI) 在统计学上与认知能力下降无关. 一项对高质量的研究的审查发现,PPI使用与认知障碍或痴呆症之间没有显著的关联.
科学领域:
- 胃肠病学 胃肠病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 最近的研究提出了质子抑制剂 (PPI) 使用与认知变化之间的联系.
- 这引发了人们对这些常见处方药的长期神经学影响的担忧.
研究的目的:
- 评估关于质子抑制剂与认知障碍之间的联系的科学证据.
- 确定PPI是否有助于痴呆症或其他认知缺陷的发展.
主要方法:
- 进行了全面的文献搜索,涵盖了2011年2月至2021年2月期间发表的研究.
- 包括的研究类型包括指南,元分析,系统审查,观察研究和实验研究.
- 从最初的393篇文章中,共选出28篇研究.
主要成果:
- 该分析包括8项系统性审查,1项临床试验,15项观察性研究,3项病例控制研究和1项横截面研究.
- 大多数研究,特别是那些具有最高证据水平的研究,都没有显示出统计学上显著的关系.
- 在使用质子抑制剂和认知障碍或痴呆的发生率之间没有明确的相关性.
结论:
- 目前的高质量证据不支持质子抑制剂与认知衰退之间的关联.
- 进一步的研究可能是有必要的,但现有的数据表明,PPI不是痴呆症的重要风险因素.
- 临床医生可以放心地说,根据当前的文献,PPI和认知障碍之间没有被证明的联系.
相关概念视频
Dementia
144
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
144
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
477
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
477
Alzheimer's Disease: Treatment
226
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226
Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
526
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
526
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
474
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
474


